Histone methylation is a fundamental epigenetic modification involving the addition of methyl groups to specific lysine or arginine residues on histone protein tails, particularly on histones H3 and H4.[1] Unlike acetylation, which generally relaxes chromatin structure to promote transcription, the functional consequences of methylation depend critically on which residue is modified and the degree of methylation (mono-, di-, or trimethylation).[1:1][2] This modification serves as a crucial regulator of chromatin architecture and gene expression programs that determine cell identity, developmental state, and adaptive responses to environmental stimuli.[2:1]
Histone methylation operates within the broader context of the chromatin landscape, where DNA is wrapped around histone octamers to form nucleosomes, the basic units of chromatin.[3] The post-translational modification of histone tails creates a "histone code" that dictates whether specific genomic regions are accessible for transcription or maintained in a transcriptionally silent state.[3:1] This epigenetic marking system allows stable yet dynamic regulation of gene expression without altering the underlying DNA sequence.
Histone methyltransferases (HMTs) catalyze the transfer of methyl groups from S-adenosylmethionine (SAM) to specific lysine or arginine residues on histone tails.[1:2] These enzymes are organized into several families based on their catalytic domains and target specificity. The SET domain-containing proteins, including SUV39H1, SUV39H2, G9a, and Pr-Set7, represent a major class of lysine methyltransferases that mediate H3K9, H3K27, and H4K20 methylation.[1:3][4] The DOT1L family members are unique in methylating H3K79 rather than lysine residues in the histone tail region.[4:1]
The specificity of HMTs ensures that particular modifications occur at defined genomic loci, establishing distinct chromatin states. For example, SUV39H1 catalyzes H3K9me3 at pericentric heterochromatin, contributing to constitutive heterochromatin maintenance and genomic stability.[1:4] G9a mediates H3K9me2 at euchromatic regions to regulate developmental gene expression programs.[1:5]
The reversible nature of histone methylation is ensured by histone demethylases (KDMs), which remove methyl groups from modified residues.[2:2] The LSD (lysine-specific demethylase) family, including LSD1 and LSD2, catalyze the oxidative demethylation of mono- and dimethylated lysine residues through a flavin-dependent mechanism.[2:3] The JmjC (Jumonji-C) domain-containing family, comprising enzymes such as KDM2A, KDM3A, KDM4A, KDM5A, and KDM6A, use Fe(II) and α-ketoglutarate-dependent oxygenase chemistry to demethylate all three methylation states on lysine residues.[2:4]
The dynamic equilibrium between methylation and demethylation allows cells to rapidly reprogram gene expression in response to developmental cues, environmental stresses, or pathological challenges. Dysregulation of this balance has been implicated in numerous diseases, including cancer and neurodegenerative disorders.[2:5][5]
H3K4 methylation, particularly H3K4me3 at gene promoters, is strongly associated with active transcription and serves as a hallmark of transcriptionally competent chromatin.[3:2] H3K4me1 is enriched at enhancers, where it marks potential regulatory elements that respond to developmental and environmental signals.[3:3] H3K36me3, catalyzed by SETD2 and other enzymes, is deposited on the bodies of actively transcribed genes and contributes to transcriptional elongation and alternative splicing.[3:4]
H3K9me3, established by SUV39H1 and related enzymes, is a canonical heterochromatin mark that recruits heterochromatin protein 1 (HP1) and enforces transcriptional silencing at pericentric and satellite repeats, as well as at specific gene loci.[1:6] H3K27me3, deposited by the Polycomb Repressive Complex 2 (PRC2), mediates facultative heterochromatin and is essential for developmental gene silencing and cell fate determination.[3:5][4:2] H4K20me3, generated by Pr-Set7 and SUV4-20H enzymes, is associated with repressive chromatin and genomic stability.[1:7]
In embryonic stem cells, certain developmental regulator genes possess bivalent domains containing both H3K4me3 (activating) and H3K27me3 (repressing) marks, keeping these genes "poised" for rapid activation upon differentiation cues.[3:6] This bivalency represents a key mechanism for maintaining pluripotency while retaining the capacity for lineage-specific gene expression.
Altered histone methylation patterns have been documented in Alzheimer's disease (AD) brains, with changes in H3K4me, H3K9me, and H3K27me observed in disease-vulnerable regions.[5:1][6] These modifications correlate with dysregulated expression of genes involved in amyloid processing, tau phosphorylation, neuroinflammation, and synaptic function.[5:2] The epigenetic changes may represent either a primary pathogenic mechanism or a secondary consequence of cellular stress and neurodegeneration.
Studies have revealed histone methylation alterations in Parkinson's disease (PD) models and patient tissue.[7] Changes in H3K9me and H3K27me have been associated with transcriptional dysregulation of genes involved in mitochondrial function, protein homeostasis, and neuronal survival.[7:1] Furthermore, alpha-synuclein aggregation may directly interfere with histone methylation machinery, propagating epigenetic dysfunction.[7:2]
Epigenetic reprogramming of glial cells through histone methylation contributes to chronic neuroinflammation in neurodegenerative diseases.[5:3][6:1] Glial cells adopt pro-inflammatory phenotypes through altered methylation of cytokine genes and matrix metalloproteinases, perpetuating neuronal damage.[6:2] Therapeutic modulation of these epigenetic states represents a potential intervention strategy.
Epigenetic therapy using small molecule inhibitors of HMTs or KDMs has shown promise in preclinical models of neurodegenerative disease.[5:4][8] Inhibitors targeting G9a, LSD1, or JMJD3 have demonstrated neuroprotective effects in cellular and animal models by modulating expression of disease-relevant genes.[5:5][8:1] However, the pleiotropic functions of histone methylation marks and the complexity of epigenetic regulation present significant challenges for therapeutic translation.
Histone methylation serves as a key mechanistic link between environmental exposures, cellular stress responses, and gene expression programs in neurodegenerative disease.[5:6][6:3] Understanding these epigenetic pathways provides insight into disease pathogenesis and identifies potential therapeutic targets. The modification intersects with broader epigenetic regulatory mechanisms including DNA methylation and histone acetylation, collectively forming the epigenetic landscape that determines neuronal survival and function.
Epigenetics in Neurodegenerative Diseases. Subcellular Biochemistry. 2025. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Epigenetics-Based Therapeutics for Neurodegenerative Disorders. Current Translational Geriatrics and Experimental Gerontology Reports. 2012. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Histone methylation: Defining the epigenetic landscape. Cell. 2012. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Histone methyltransferases: Novel therapeutic targets in cancer and neurodegeneration. Pharmacology and Therapeutics. 2021. ↩︎ ↩︎ ↩︎
Histone methylation in Alzheimer's disease: From mechanism to therapy. Ageing Research Reviews. 2024. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Epigenetic regulation in neurodegenerative diseases. Neural Regeneration Research. 2023. ↩︎ ↩︎ ↩︎ ↩︎
Epigenetic dysregulation in Parkinson's disease. Journal of Parkinson's Disease. 2022. ↩︎ ↩︎ ↩︎
Targeting epigenetic regulators for neurodegenerative disease therapy. Neurobiology of Disease. 2022. ↩︎ ↩︎